Your browser doesn't support javascript.
loading
An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
Bassolas-Molina, Helena; Raymond, Ernest; Labadia, Mark; Wahle, Joseph; Ferrer-Picón, Elena; Panzenbeck, Mark; Zheng, Jie; Harcken, Christian; Hughes, Robert; Turner, Michael; Smith, Dustin; Calderón-Gómez, Elisabeth; Esteller, Míriam; Carrasco, Anna; Esteve, Maria; Dotti, Isabella; Corraliza, Ana Maria; Masamunt, Maria Carme; Arajol, Clàudia; Guardiola, Jordi; Ricart, Elena; Nabozny, Gerald; Salas, Azucena.
Afiliação
  • Bassolas-Molina H; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Raymond E; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Labadia M; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Wahle J; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Ferrer-Picón E; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Panzenbeck M; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Zheng J; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Harcken C; Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Hughes R; Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Turner M; Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Smith D; Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
  • Calderón-Gómez E; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Esteller M; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Carrasco A; Department of Gastroenterology, Hospital Universitari Mutua Terrassa, Barcelona, Spain.
  • Esteve M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
  • Dotti I; Department of Gastroenterology, Hospital Universitari Mutua Terrassa, Barcelona, Spain.
  • Corraliza AM; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
  • Masamunt MC; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Arajol C; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Guardiola J; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
  • Ricart E; Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
  • Nabozny G; Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
  • Salas A; Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.
Front Immunol ; 9: 2307, 2018.
Article em En | MEDLINE | ID: mdl-30405600

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Interleucina-17 / Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares / Mucosa Intestinal Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Crohn / Interleucina-17 / Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares / Mucosa Intestinal Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha País de publicação: Suíça